612 related articles for article (PubMed ID: 3306520)
1. Contraception for the perimenopausal patient.
Upton GV
Obstet Gynecol Clin North Am; 1987 Mar; 14(1):207-27. PubMed ID: 3306520
[TBL] [Abstract][Full Text] [Related]
2. The contraceptive and hormonal requirements of the premenopausal woman: the years from forty to fifty.
Upton GV
Int J Fertil; 1986; 30(4):44-52. PubMed ID: 2890595
[TBL] [Abstract][Full Text] [Related]
3. The adverse effects of hormonal therapy.
Bush TL
Cardiol Clin; 1986 Feb; 4(1):145-52. PubMed ID: 3518931
[TBL] [Abstract][Full Text] [Related]
4. Epidemiologic aspects of exogenous progestagens in relation to their role in pathogenesis of human breast cancer.
van Leeuwen FE
Acta Endocrinol (Copenh); 1991; 125 Suppl 1():13-26. PubMed ID: 1801500
[TBL] [Abstract][Full Text] [Related]
5. The prevention of breast cancer through reduced ovarian steroid exposure.
Spicer DV; Pike MC
Acta Oncol; 1992; 31(2):167-74. PubMed ID: 1622631
[TBL] [Abstract][Full Text] [Related]
6. Current perspectives on combination oral contraceptives.
Smith MA; Youngkin EQ
Clin Pharm; 1984; 3(5):485-96. PubMed ID: 6386284
[TBL] [Abstract][Full Text] [Related]
7. Hormonal contraception.
Baird DT; Glasier AF
N Engl J Med; 1993 May; 328(21):1543-9. PubMed ID: 8479492
[TBL] [Abstract][Full Text] [Related]
8. Changes in lipoproteins with various sex steroids.
Teran AZ; Greenblatt RB; Chaddha JS
Obstet Gynecol Clin North Am; 1987 Mar; 14(1):107-19. PubMed ID: 3306515
[TBL] [Abstract][Full Text] [Related]
9. [Contraception at risk].
Dubois C; Le Strat N
Rev Prat; 1987 Sep; 37(38):2293-301. PubMed ID: 3659796
[TBL] [Abstract][Full Text] [Related]
10. Alternate delivery systems for contraceptive progestogens.
Ginsburg KA; Moghissi KS
Fertil Steril; 1988 May; 49(5 Suppl 2):16S-30S. PubMed ID: 3282932
[TBL] [Abstract][Full Text] [Related]
11. Sex steroids and breast cancer prevention.
Spicer DV; Pike MC
J Natl Cancer Inst Monogr; 1994; (16):139-47. PubMed ID: 7999456
[TBL] [Abstract][Full Text] [Related]
12. [Potential advantages of triphasic combined oral contraceptives in the light of recent epidemiological and endocrinometabolic data].
Gaspard U; Dubois M
Contracept Fertil Sex (Paris); 1982 Sep; 10(9):551-60. PubMed ID: 12311606
[TBL] [Abstract][Full Text] [Related]
13. [Cardiovascular risks of oral contraceptives: dose-response relationship].
Kelleher CC
Contracept Fertil Sex (Paris); 1991 Apr; 19(4):285-8. PubMed ID: 12343220
[TBL] [Abstract][Full Text] [Related]
14. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
15. [Oral contraception: failures and risks].
Foussard-blanpin O; Paillot-renaud P; Bruneau-bigot A
Lyon Pharm; 1984 Nov; 35(6):385-93. PubMed ID: 12280590
[TBL] [Abstract][Full Text] [Related]
16. Transdermal delivery of sex steroids for hormone replacement therapy and contraception. A review of principles and practice.
Henzl MR; Loomba PK
J Reprod Med; 2003 Jul; 48(7):525-40. PubMed ID: 12953327
[TBL] [Abstract][Full Text] [Related]
17. Lipid and lipoprotein changes in relation to oral contraception and hormonal replacement therapy.
Burkman RT
Fertil Steril; 1988 May; 49(5 Suppl 2):39S-50S. PubMed ID: 3282934
[TBL] [Abstract][Full Text] [Related]
18. [Pros and cons of triphasic oral contraception].
Berdah J
Contracept Fertil Sex (Paris); 1985 Dec; 13(12):1205-10. PubMed ID: 12267512
[TBL] [Abstract][Full Text] [Related]
19. Hormone replacement therapy and cancer.
Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
[TBL] [Abstract][Full Text] [Related]
20. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.
Genazzani AR; Gadducci A; Gambacciani M
Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
